About kahler disease
What is kahler disease?
Multiple myeloma is a rare form of cancer (1% of malignancy) characterized by excessive production (proliferation) and improper function of certain cells (plasma cells) found in the bone marrow. Plasma cells, which are a type of white blood cell, are produced in the bone marrow and normally reside there. Excessive plasma cells may eventually mass together to form a tumor or tumors in various sites of the body, especially the bone marrow. If only a single tumor is present, the term solitary plasmacytoma is used. When multiple tumors are present, the term multiple myeloma is used. Plasma cells are a key component of the immune system and secrete a substance known as immunoglobulin proteins (M-proteins), a type of antibody. Antibodies are special proteins that the body produces to combat invading microorganisms, toxins, or other foreign substances. Overproduction of plasma cells in affected individuals results in abnormally high levels of these proteins within the body, referred to as M proteins
Major symptoms of multiple myeloma may include bone pain, especially in the back and the ribs; low levels of circulating red blood cells (anemia) resulting in weakness, fatigue, and lack of color (pallor); and kidney (renal) abnormalities. In some cases, affected individuals are more susceptible to bacterial infections such as pneumonia. The cause of multiple myeloma is unknown.
What are the symptoms for kahler disease?
The specific symptoms, age of onset, and rate of progression of multiple myeloma varies from patient to patient. Some affected individuals will not exhibit any symptoms (asymptomatic). Multiple myeloma may progress to cause life-threatening complications. It is important to note that affected individuals will not have all the symptoms listed below.
The most common symptom associated with multiple myeloma is bone pain, usually of the lower back or ribs. In most patients, movement worsens the pain, which may be mild, moderate or severe. Affected individuals are usually more susceptible to fractures than the general population and may experience repeated fractures of affected bones. The bones of the spine may become involved, potentially collapsing and resulting in spinal cord compression. Compression of the spinal cord results in pain, Weakness and numbness in the arms and legs.
Another possible sign of multiple myeloma is an elevated level of calcium in the blood, a condition called hypercalcemia. This occurs because damage to bones often results in the release of calcium into the bloodstream. Abnormally high levels of calcium may result in nausea, lack of appetite, fatigue, abdominal pain, muscle Pain and weakness, excessive thirst, and/or confusion.
Overproduction of plasma cells may also hinder the production and decrease the effectiveness of other cells of the body resulting in a variety of symptoms. Affected individuals may experience low levels of circulating red blood cells (anemia) resulting in weakness, fatigue, dizziness, shortness of breath, and lack of color (pallor). Affected individuals may also experience low levels of cells that assist in clotting (platelets), a condition known as thrombocytopenia. Symptoms associated with thrombocytopenia include Abnormal bleeding episodes that often result in purplish discoloration of the skin resulting from bleeding (hemorrhaging) of small blood vessels near the surface of the skin (purpura). Rarely, affected individuals may experience repeated nosebleeds (epistaxis).
Affected individuals may also have low levels or reduced effectiveness of white blood cells, which weakens the immune system and results in a higher susceptibility than the general population to developing recurrent bacterial infections. The most common infection is pneumonia. In some patients, recurrent infections may be the first apparent symptom of multiple myeloma.
Individuals with multiple myeloma may also develop kidney abnormalities. In some patients, hypercalcemia may cause kidney damage. Abnormal proteins found in the blood or urine (M-proteins), which are produced by myeloma cells, may cause kidney damage (myeloma kidney). Kidney abnormalities may develop slowly or rapidly, and may eventually progress to cause kidney (renal) failure.
Rarely, individuals with multiple myeloma may have an abnormally large liver (hepatomegaly) or spleen (splenomegaly).Rarely, multiple myeloma may occur in association with other disorders. The three most common disorders that may occur in association with multiple myeloma include hyperviscosity syndrome, cryoglobulinemia, or amyloidosis.
Hyperviscosity syndrome is characterized by the blood becoming abnormally thick and sticky due to the abnormal accumulation of M-proteins in the blood. As a result blood flow is slowed. Hyperviscosity syndrome may cause headaches, nose bleeding, fatigue, frequent bruising, gastrointestinal bleeding, and vision abnormalities such as disease of the retina (retinopathy). Cryoglobulinemia is a rare disorder that occurs due to the accumulation of abnormal proteins (cryoglobulins) in the bloodstream. These proteins thicken or gel on exposure to cold. In some patients there are no symptoms and in others a variety of symptoms may develop. The most common symptoms are joint Pain (arthralgia), Pain and numbness in the fingers and toes in response to cold (Raynaud’s phenomenon), weakness, and purpura.
Amyloidosis is a rare disorder characterized by the abnormal accumulation of a fibrous protein (amyloidosis) in tissues of the body. The excessive accumulation of amyloid causes an affected organ to malfunction. (For more information on this disorder, see the Related Disorders section below.)
What are the causes for kahler disease?
The exact cause of multiple myeloma is not known. Symptoms occur as a result of a process that is initiated by the abnormal multiplication of plasma cells in bone marrow. Scientists suspect there may be a variety of causes that may include environmental factors (e.g., the effects of exposure to radiation), genetic abnormalities, and/or additional factors that may play varying contributing roles. Exposure to dioxin has been associated with an increased risk of myeloma.
One factor of interest to researchers is that many myeloma cells have been found to be missing all or part of chromosome 13. Also, the development of multiple myeloma is preceded in virtually all cases by a condition called monoclonal gammopathy of undetermined significance or MGUS (see Related Disorders section). The cause of MGUS is not known.
The specific symptoms of multiple myeloma result from excessive and unnecessary growth (neoplastic proliferation) of plasma cells.
What are the treatments for kahler disease?
The diagnosis and therapeutic management of multiple myeloma may require the coordinated efforts of a team of medical professionals, such as physicians who specialize in the diagnosis and treatment of cancer (medical oncologists), disorders of the blood and blood-forming tissues (hematologists), or the use of radiation to treat cancers (radiation oncologists); oncology nurses; surgeons; dietitians; and/or other professionals.
Specific therapeutic procedures and interventions may vary, depending upon numerous factors, such as disease stage; tumor size; the presence or absence of certain symptoms; individual’s age and general health; and/or other elements. Decisions concerning the use of particular drug regimens and/or other treatments should be made by physicians and other members of the health care team in careful consultation with the patient based upon the specifics of his or her medical history; a thorough discussion of the potential benefits and risks, including possible side effects and long-term effects; patient preference; and other appropriate factors.
Some affected individuals may have a slow developing form of multiple myeloma that progresses over many years, often without symptoms (asymptomatic). Such individuals, and individuals with similar conditions like smoldering multiple myeloma and MGUS, may not require treatment. However, these individuals should be routinely monitored so that treatment can begin if symptoms appear.
The treatment of multiple myeloma usually involves chemotherapy to reduce the numbers of abnormal plasma cells, drugs to help fight infection (e.g., antibiotics), and medications to reduce pain (analgesic drugs). Additional treatment may include the use of high energy x-rays (radiation therapy) to destroy cancer cells and reduce bone masses that may develop. The use of new biologic drugs may also be recommended. If affected individuals experience involvement of the kidneys, fluids may need to be administered to avoid dehydration.
The following link provides information from the National Cancer Institute about medications that have been approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma:
Stem-cell transplantation along with high-dose chemotherapy is regularly used for the treatment of multiple myeloma. Stem cells, which reside in the bone marrow, function as “parent” cells, undergoing a series of divisions that result in the formation of all the different types of blood cells (e.g., red blood cell, platelets, etc.).
Other treatment is symptomatic and supportive.
What are the risk factors for kahler disease?
Experts aren't sure what causes multiple myeloma. But you're more likely to get it if:
- You're older than 65
- You're male
- You're African American
- You have a family member with it
- You're overweight or obese
- You've been exposed to radiation
- You've had contact with chemicals used in rubber manufacturing, woodworking, or firefighting; or in herbicides